Institut für angewandte Pathologie
Research facility
Location:
Speyer,
Germany (DE)
Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”: [ESMO Open 9 (2024) 103703](S2059702924014728)(10.1016/j.esmoop.2024.103703) (2025)
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, et al.
Journal article, Erratum
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) (2024)
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, et al.
Journal article
DCC is expressed in a CD166-positive subpopulation of chondrocytes in human osteoarthritic cartilage and modulates CRE activity (2014)
Bosserhoff AK, Hofmeister S, Ruedel A, Schubert T
Journal article